Gritstone Bio Total Long-Term Assets 2017-2024 | GRTSQ
Gritstone Bio total long-term assets from 2017 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
Gritstone Bio Annual Total Long-Term Assets
(Millions of US $) |
| 2023 |
$90 |
| 2022 |
$58 |
| 2021 |
$58 |
| 2020 |
$46 |
| 2019 |
$53 |
| 2018 |
$32 |
| 2017 |
$29 |
| 2016 |
$8 |
Gritstone Bio Quarterly Total Long-Term Assets
(Millions of US $) |
| 2024-06-30 |
$82 |
| 2024-03-31 |
$85 |
| 2023-12-31 |
$90 |
| 2023-09-30 |
$96 |
| 2023-06-30 |
$100 |
| 2023-03-31 |
$55 |
| 2022-12-31 |
$58 |
| 2022-09-30 |
$52 |
| 2022-06-30 |
$52 |
| 2022-03-31 |
$51 |
| 2021-12-31 |
$58 |
| 2021-09-30 |
$53 |
| 2021-06-30 |
$47 |
| 2021-03-31 |
$44 |
| 2020-12-31 |
$46 |
| 2020-09-30 |
$49 |
| 2020-06-30 |
$51 |
| 2020-03-31 |
$51 |
| 2019-12-31 |
$53 |
| 2019-09-30 |
$54 |
| 2019-06-30 |
$43 |
| 2019-03-31 |
$40 |
| 2018-12-31 |
$32 |
| 2018-09-30 |
$29 |
| 2018-06-30 |
|
| 2018-03-31 |
|
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2016-12-31 |
$9 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
|
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|
